"Can I drink on peptides?" is one of the most common questions in the research-peptide market, and it is usually answered with a reassurance or a warning that cites nothing. There is a checkable place to start: the approved peptide medicines have labels, and US labels must state known interactions. We read 21 of them. This page reports what they say, describes the one controlled study of alcohol with a peptide drug, and sets out how little exists for anything sold as a research chemical. GLP-1 drugs are excluded here — their alcohol record is covered in full by glp1ledger's GLP-1 and alcohol page.
The label census
Method. On 2026-10-09 we queried openFDA's drug-label endpoint for each active ingredient below, took the most recently effective label, and searched its full text for "alcohol". Mentions of benzyl, cetyl or isopropyl alcohol, alcohol swabs and instructions to clean the skin or a pen were set aside; what remained is any statement about drinking. One result for oxytocin was a homeopathic product rather than the prescription drug, and was dropped.
| Medicine (brand on the label read) | Label effective | Statement about drinking alcohol |
|---|---|---|
| Bremelanotide (Vyleesi) | 2025-11-13 | Yes — alcohol interaction study; naltrexone warning |
| Pramlintide (SymlinPen) | 2019-12-18 | Yes — may increase the chance of severe low blood sugar |
| Insulin glargine (Basaglar) | 2026-06-16 | Yes — alcohol may increase or decrease the glucose-lowering effect |
| Tesamorelin (Egrifta SV) | 2026-07-29 | No |
| Teriparatide (Forteo) | 2026-08-03 | No |
| Abaloparatide (Tymlos) | 2026-08-11 | No |
| Octreotide | 2026-01-30 | No |
| Lanreotide | 2025-02-01 | No |
| Leuprolide (Vabrinty) | 2026-04-30 | No |
| Calcitonin salmon | 2026-03-06 | No |
| Setmelanotide (Imcivree) | 2026-04-01 | No |
| Elamipretide (Forzinity) | 2025-12-10 | No |
| Vasopressin | 2025-12-18 | No |
| Desmopressin (tablets) | 2025-11-13 | No |
| Cetrorelix (Cetrotide) | 2025-09-22 | No |
| Ganirelix | 2026-05-11 | No |
| Glucagon (Baqsimi) | 2026-06-19 | No |
| Linaclotide (Linzess) | 2026-05-21 | No |
| Plecanatide (Trulance) | 2024-04-04 | No |
| Mecasermin (Increlex) | 2026-05-18 | No |
| Somatropin (Humatrope) | 2026-08-20 | No |
Three of 21 labels — 14% — say anything about drinking. Two of the three say it for the same reason, and it has nothing to do with peptides as a class: insulin and pramlintide lower blood glucose, and alcohol blocks the liver's release of glucose, so the combination raises the risk of severe hypoglycaemia. The Basaglar label lists alcohol among drugs that "may increase or decrease the blood glucose lowering effect"; Symlin's patient information says drinking alcohol "may increase your chances of getting severe low blood sugar". Our FDA-approved peptides census lists what each of these medicines is approved for.
What the other 18 labels show is narrower than it looks. A label that is silent on alcohol means no interaction was identified in the development programme or required by FDA — not that the combination was tested and found harmless. Most of these labels describe no alcohol study at all.
The one controlled study: bremelanotide with three drinks
Only one label in the census describes an experiment. The Vyleesi (bremelanotide) label reports a placebo-controlled, randomised, double-blind, three-way crossover study in 12 healthy men and 12 healthy women. Each was given a 20 mg intranasal dose of bremelanotide — which reaches a peak level about 2.5 times that of the approved injection — ten minutes after either a placebo drink or 0.6 g/kg of ethanol, which the label equates to three 12-ounce beers, three 5-ounce glasses of wine or three shots of 80-proof spirit for a 70 kg person.
| Finding, as the label states it | |
|---|---|
| Alcohol and bremelanotide's pharmacokinetics | No effect |
| Flushing | More frequent with bremelanotide + alcohol than alcohol alone; similar to bremelanotide alone |
| Headache | More frequent with bremelanotide + alcohol than bremelanotide alone; similar to alcohol alone |
| Abnormal blood-pressure drops on standing | Comparable to alcohol alone |
| Other adverse reactions | Similar across groups |
The same label carries a second, different warning: bremelanotide may slow stomach emptying and lower blood levels of oral naltrexone, so the two should not be combined when naltrexone is being used for alcohol or opioid dependence. The full side-effect record is on our PT-141 side-effects page.
Research peptides: no human study exists
For the compounds sold as research chemicals — BPC-157, TB-500, ipamorelin, CJC-1295, sermorelin blends, MOTS-c and the rest — there is no label, and we found no study in people that gave any of them together with alcohol. What exists instead is a small animal literature that studies the peptides as possible treatments for alcohol harm:
- BPC-157. A Croatian group gave BPC-157 to mice receiving a large intraperitoneal dose of ethanol (4 g/kg), which produced anaesthesia, hypothermia and 25% mortality in controls; the peptide given before or after the alcohol opposed the intoxication, and given after abrupt withdrawal it attenuated withdrawal signs over 24 hours (Blagaic 2004, PMID 15381050; follow-up 2006, PMID 16369461). These are mouse experiments by the group that developed the peptide, and they test rescue from intoxication, not the safety of drinking during use. How BPC-157's wider record looks is on our BPC-157 side-effects page.
- DSIP. In 1984, intravenous DSIP was given to 47 people in alcohol withdrawal and 60 in opiate withdrawal as a treatment; FDA's 2026 review counts the adverse events from that study (PMID 6548969). The details are on our DSIP side-effects page.
Nothing in that literature describes what happens when a person using a research peptide drinks. The honest answer to the most common version of the question is that it has not been studied.
The alcohol that is on the label: benzyl alcohol
The word "alcohol" appears on a great deal of peptide paperwork for an unrelated reason. Benzyl alcohol, typically at 0.9%, is the preservative in bacteriostatic water and in several multi-dose peptide injections. It is not the ethanol in drinks and has nothing to do with the interaction question, though it carries its own label warnings — covered on our bacteriostatic water page.
What is not established
- Any interaction between alcohol and any research peptide in people — none has been studied.
- Whether drinking changes how injected peptides are absorbed — studied only for intranasal bremelanotide.
- Anything about the contents of research vials, which are not the products these labels describe — see what research-use-only labelling means.
The decision about drinking while using any medicine or research compound — especially one that affects blood sugar, blood pressure or the liver — belongs with a clinician or pharmacist; for approved medicines, the label is the document to bring. Our broader are peptides safe? page sets out how the safety record differs between approved, compounded and research-use products.
Sources and dates
- openFDA drug label endpoint, most recently effective label per active ingredient for the 21 medicines in the table, full text searched for "alcohol", queried 2026-10-09. Set ids include Vyleesi f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf (section 12.3, Alcohol Interaction; section 7.2), SymlinPen 4aea30ff-eb0d-45c1-b114-3127966328ff, Basaglar 0ad21db3-2b1c-4ed9-a687-bdd6a74d0aae (section 7), Egrifta SV 3d783378-b02d-4f19-99dd-0fc91a042224.
- Blagaic AB, Blagaic V, Romic Z, Sikiric P. The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in mice. Eur J Pharmacol. 2004;499(3):285-90. PMID 15381050.
- Boban-Blagaic A et al. The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in mice. The effect of N(G)-nitro-L-arginine methyl ester and L-arginine. Med Sci Monit. 2006. PMID 16369461.
- Dick P et al. DSIP in the treatment of withdrawal syndromes from alcohol and opiates. Eur Neurol. 1984;23(5):364-71. PMID 6548969.
- PubMed searches for alcohol or ethanol with BPC-157 and with ten other research peptides in human studies, run 2026-10-09: no study of co-use found.